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Abstract: The Discharge Medicines Review (DMR) referral system, Refer-to-Pharmacy (RTP), Phar-
mOutcomes and Help for Harry are UK transfer of care systems that aim to reduce the risks associated
with hospital discharge. These systems use technology to facilitate the transmission of discharge
information to community pharmacy, allowing community pharmacists to provide an adherence-
support service. Despite the evidence that these systems benefit patient safety, there is a paucity of
literature on their use. This study aimed to describe, compare and contrast these systems to highlight
areas that could inform good practice recommendations. A rapid literature review was completed,
and from the twenty-six sources of literature that were synthesised, three themes were identified
for further exploration in semi-structured interviews with key informants: implementation, system
attributes and stakeholder engagement. The key informants were purposively sampled for their
role in the development and/or strategic implementation of each transfer of care system (n = 4).
Audio recordings were transcribed ad verbatim and analysed both deductively and inductively. One
interview was undertaken for each of the DMR, RTP and PharmOutcomes systems. Although all
systems shared the same aim, differences were identified such as automated feedback for referrals,
marketing strategies and practitioner accountability. Good practice recommendations suggested in
this study could be applied to the future development of such systems.
Keywords: transfer of care; hospital discharge; community pharmacy; medicines optimisation;
medicines adherence; healthcare technology
1. Introduction
Patient transfer from hospital to the community is a process that is associated with
many risks including medication errors, care discontinuity and subsequent hospital read-
mission [1]. Reducing the risk of medication-related harm during transfer of care, including
hospital discharge, is considered an international priority as highlighted by the Medication
Without Harm report from the World Health Organisation [2]. In the United Kingdom
(UK), improving the transfer of information at hospital discharge has been prioritised
by the King’s Fund, an independent organisation that aims to improve health and social
care in England [3]. There have been numerous attempts to reduce the risks associated
with transfer of care, typically focusing on specific aspects of the discharge process in-
cluding electronic transmission of discharge information from hospital to community,
post-discharge medicines reconciliation, and post-discharge support [4]. These attempts
have been combined to different extents, creating more co-ordinated approaches called
transfer of care systems. For many of these systems, community pharmacists are the
healthcare professionals that provide post-discharge support [5]. This professional group
Pharmacy 2021, 9, 36. https://doi.org/10.3390/pharmacy9010036 https://www.mdpi.com/journal/pharmacy
Pharmacy 2021, 9, 36 2 of 18
can effectively identify and rectify post-discharge medication-related issues which could
have resulted in patient harm, as evidenced by a recent systematic review [5]. Interna-
tional examples of these systems include the hospital-initiated Home Medication Review
in Australia and the IBOM-1 protocol in the Netherlands, both involving post-discharge
medicines adherence-support provided by community pharmacists [6,7]. Some of these
systems use technology to facilitate the transmission of discharge information from hospital
to community pharmacy.
In the UK, the National Health Service (NHS) is the umbrella term for the four health
systems of the UK: England, Scotland, Wales and Northern Ireland. It is moving towards
more technology-based solutions to improve patient care and to free healthcare staff
capacity, as described by NHS England’s long-term plan and an independent review of
technology utilisation in the NHS, the Topol Review [8,9]. Transfer of care systems are no
exception and have been developed in the UK using technology.
Since health is one of the devolved powers across these four devolved authorities of
the UK [10], they are each responsible for their own health policies, including the digital
strategy for health. As a result, there are multiple technology-supported transfer of care
systems currently available in the UK, depending on locality. For example, in certain
parts of England, PharmOutcomes, or Refer to Pharmacy or Help for Harry have been
utilised, whereas in Wales, a national Discharge Medicines Review (DMR) system has
been developed [11–14]. Each of these systems use technology to provide community
pharmacists access to discharge information for their patients, allowing them to provide
post-discharge medicines support to patients via a range of a commissioned services, which
differ between countries. The evidence base supporting the use of some of these systems
and the services they underpin is growing, with proven patient safety benefits, including
identifying medication discrepancies and an association with a reduction in the risk of
hospital readmission [13,15–17]. Despite the benefits of these systems, there is a paucity of
published literature on their strategic implementation, processes and use.
With the increased emphasis on delivering healthcare embracing digital technologies,
outlined in the Topol review in 2019 [9], combined with the renewed priority that the
World Health Organisation placed on medication safety across transitions of care [18], it is
imperative to construct the evidence base to support the development of transfer of care
systems, both internationally and in the UK.
In this study, we aimed to describe, compare and contrast the current UK technology-
supported transfer of care systems to inform good practice recommendations.
2. Materials and Methods
To achieve the study aims, a multi-method approach was used. This encompassed
two methods which supplemented each-other. This is distinct to mixed methods research
which uses both qualitative and quantitative methods, aiming to integrate the results to
meet the research aims [19,20].
A rapid literature review, inclusive of grey literature, was performed to map the
generic process of each system and to gather information about their provision and how
they were strategically implemented. The literature identified through this approach
was synthesised but lacked information regarding elements of the development and the
strategic approach to implementation of the systems. To further explore the gaps identified
from the literature, semi-structured key informant interviews were used [21,22].
2.1. Method 1: Rapid Literature Review
As there is a paucity of published literature on technology-supported transfer of care
systems, the rapid literature review was developed to ensure all key literature was captured.
Two stages were used to index published literature, but also to include a more specific
search for grey literature. The first stage was a structured literature search in databases that
index journals related to healthcare research. The information gathered from this approach
was then supplemented with a targeted literature search in grey literature sources such as
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YouTube and National Institute for Health and Care Excellence (NICE), using more specific
search terms.
2.1.1. Search Strategy and Resources
The search strategy was developed iteratively to index all resources relevant to UK
technology-supported transfer of care systems. The authors were aware that there were no
well-established electronic transfer of care systems developed before the DMR service in
2011, and therefore, the search was restricted to the last ten years to ensure the development
of any active systems were included. The exclusion criteria were articles with no relevance
to UK transfer of care systems. The search strategy for both stages of the rapid literature
review is described in Table 1.
Table 1. Search strategy for literature review to describe the implementation and processes of UK
technology-supported transfer of care systems.
Eligibility Criteria
Published between January 2009 and November 2018
Published in English
Relates to UK technology-supported transfer of care systems
Structured Literature Search





“Care adj3 transfer” OR














Including only literature indexed under
‘Nursing’, ‘Health professions’, ‘Medicine’,
‘Psychology’, ‘Social Sciences’, ‘Toxicology and




















No formal tool was used to assess the quality of indexed articles before inclusion, as
the aim was to describe, compare and contrast the different systems.
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2.1.3. Synthesis of Literature
The final literature identified from both stages of the rapid literature search was com-
bined and then synthesised to describe the generic process for each technology-supported
transfer of care system and to compare them. To allow the timely synthesis of literature, one
author performed the synthesis (RJ) and discussed frequently with another two authors
(KH and EM), a method supported by the literature [23]. Once the literature had been
synthesised and the systems were compared, a number of areas were identified where not
enough information was retrieved to allow an in-depth comparison of the systems. It was
therefore decided to supplement the literature review with key stakeholder interviews.
2.2. Method 2: Key Stakeholder Interviews (29th May to 8th July 2019)
The semi-structured key informant interviews were performed either face-to-face or
by telephone. A generic qualitative approach was used to supplement the information
identified from the literature review [21,22]. The interview schedule (Appendix A) sought
clarity around the description of each system, and explored concepts around the attributes
of each system, their referral processes and the approach to their strategic implementation.
To improve transparency of reporting, the Standards for Reporting Qualitative Research
has been completed and attached as Appendix B [24].
2.2.1. Study Approvals
Ethical approval was granted by the Cardiff School of Pharmacy & Pharmaceutical
Sciences Ethics Committee on 8 March 2019 (1819-11). As some participants were NHS em-
ployees, the study was registered with their employing healthcare authority where required.
2.2.2. Participants and Recruitment
The population were individuals who were involved with the development and/or
strategic implementation of a UK technology-supported transfer of care system. The
sampling frame was identified from the literature, and key informants were purposively
sampled for each of the four systems [11].
One participant for each system was considered appropriate as the aim was not to
reach saturation, but to further describe aspects of each system.
All four participants were invited to participate by email with an attached participant
information leaflet and consent form. A reminder email was sent to non-responders after
two weeks.
2.2.3. Data Collection and Analysis
Interviews were audio-recorded with consent, transcribed ad verbatim using Microsoft
Word and identifying information was removed to ensure confidentiality [25]. A mixed
thematic analysis was performed using NVivo (version 11) [25]. Firstly, the data were
deductively analysed, searching for concepts identified from the literature. The data were
then analysed inductively, as described by Braun and Clarke [26], to construct themes
from any other information that was not captured in the deductive analysis. RJ and KH
independently coded the data and a meeting was held to confirm that there was inter-coder
reliability [21].
2.2.4. Reflexivity
RJ is a practising community pharmacist in Wales with experience using the DMR
referral system. This could introduce bias as he had preconceived ideas of barriers and
facilitators to engaging with the DMR referral system. To mitigate the effects of potential
bias, a reflective diary was kept through the process of collecting data, transcribing and
data analysis. This allowed reflection on the potential effect of bias at every stage of the
research process, allowing interpretation to be data-driven.
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3. Results
3.1. Method 1 Results: Rapid Literature Review
The rapid literature review was performed between 8 October and 25 November 2018.
The structured literature search identified eleven relevant results for inclusion. The
number of hits and refinement of the literature is described in a PRISMA flow diagram in
Figure 1. No additional literature was discovered through reference screening.
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Figure 1. PRISMA flow diagram describing the refinement of the structured literature search.
Fourteen additional sources were identified from the targeted literature search. One
further source was identified through reference screening of the targeted literature search
results. A summary of the literature can be found in Supplementary Materials Table S1. The
twenty-six sources of literature that were id ntified from this review w re synthesised to
first describe the generic processes for each system and to then dentify areas t at contrast.
Three broad concepts were identified from the literature in which the systems contrast:
implementation, stakeholder engagement and system attributes.
3.1.1. Transfer of Care System Processes
The DMR referral system, Refer-to-Pharmacy and PharmOutcomes used IT platforms
to facilitate community pharmacist access to a patient’s discharge information, whereas
Help for Harry used fax transmission. This information was transferred to support the
community pharmacist in providing post-discharge support. For the DMR referral system
and Help for Harry, this information was specifically to support the completion of an
adherence-support service. Refer-To-Pharmacy and PharmOutcomes referrals could be for
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adherence-support services or could be for information only, for patients who have their
medicines dispensed into compliance aids, for care home residents and for the provision of
other post-discharge support services, such as smoking cessation [27,28].
Synthesis of the literature was used to describe the transfer of care system processes
as shown in Figure 2 [11,28–30].




Figure 2. Process map for UK technology-supported transfer of care systems. Footnotes denoted by † are used to further 
describe selected aspects of the figure. † Discharge information is stored within the Welsh Care Records Service and ac-
cessed via the all-Wales shared community pharmacy IT platform, Choose Pharmacy. Only the nominated pharmacy is 
notified of discharge, but discharge information can be accessed by any pharmacist with patient consent. †† Information 
available only to the nominated pharmacy. 
Notifications 
Figure 2. Process map for UK technology-supported transfer of care systems. Footnotes denoted by † are used to further
describe selected aspects of the figure. † Discharge information is stored within the Welsh Care Recor s Service and accessed
via the all-Wales shared community pharmacy IT platform, Choose Pharmacy. Only the nominated pharmacy is notified of
discharge, but discharge information can be accessed by any pharmacist with patient consent. †† Information available only
to the nominated pharmacy.
3.1.2. Identifying Differences
Some features of the transfer of care systems that contrast are described in Table 2,
whilst areas requiring more detailed explanation are described below.
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Table 2. Key similarities and differences between the UK technology-supported transfer of care systems.
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GBP 37 per DMR GBP 20–28 per NMSGBP 28 per MUR
GBP 20–28 per NMS
GBP 28 per MUR
GBP 20–28 per NMS
GBP 28 per MUR
† The DMR service is a commissioned community pharmacy service in Wales which consists of medicines reconciliation (part one) and
adherence-support (part two). †† MUR and NMS are community pharmacy services that are commissioned in England and that provide
medicines adherence-support. Payment for the NMS service is graduated; contractors will be paid higher rates per service if they have
provided more NMSs in that financial year relative to the maximum of four hundred.
Notifications
Each system notifies the community pharmacy about the patient’s hospital status.
Refer-to-Pharmacy and PharmOutcomes send a notification when a patient is referred to
inform the pharmacy that their patient is in hospital, and at discharge to inform them that
the patient is going home [32,36]. The DMR referral system and Help for Harry only notify
the community pharmacy of the patient’s discharge.
Help for Harry sends notifications by fax where all the other systems send anonymised
notifications electronically [11,30]. These anonymised notifications contain no patient
details but inform the community pharmacist that they have discharge information ready
to access. DMR referral notifications can be sent through the NHS email network or via the
all-Wales shared community pharmacy IT platform, Choose Pharmacy. Refer-to-Pharmacy
and PharmOutcomes notifications can also be sent through the NHS email network, and
also to personal email addresses [27,30,37]. A USB device called a Pharmalarm can be
purchased for use with PharmOutcomes, which flashes on receipt of notifications [32].
IT Interoperability
The extent to which the transfer of care systems were integrated with existing commu-
nity and hospital IT systems varied. Interoperability with either of these IT systems would
mean that practitioners did not have to manually transcribe discharge information from
their IT system into the transfer of care system, or vice-versa. The DMR referral system
and Refer-to-Pharmacy are fully interoperable with hospital IT systems, allowing seamless
referrals from the hospital without requiring additional data entry [28,30]. The majority of
hospital IT systems do not integrate with PharmOutcomes, requiring the patient informa-
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tion to be manually transcribed into the system. Some CCGs have negotiated individually
with PharmOutcomes such that it is interoperable with their systems, for an additional
cost [29,32]. Refer-to-Pharmacy and PharmOutcomes referrals are not interoperable with
community pharmacy IT systems. In practical terms, this means that once a community
pharmacy has received a referral, they will have to enter the patient details separately into
their relevant systems for providing advanced pharmacy services, such as the NMS and
dMUR [27,37]. In contrast, the DMR referral system is fully interoperable with Choose
Pharmacy. All the fields for completing a DMR will be auto-filled, requiring no manual
transcription [30]. Help for Harry uses fax transmission; therefore, it is not interoperable
with either hospital or community pharmacy IT systems [11].
Management of Patient Consent
Consent for all transfer of care systems is required in two stages. The first stage of
consent is for making the discharge information available for community pharmacists and
then consent is required for the provision of the follow-up service [17,30]. Consent for
information transfer is sought verbally by hospital pharmacists or pharmacy technicians.
For PharmOutcomes and Refer-to-Pharmacy this will be sought on admission, allowing
both admission and discharge notifications to be generated [28,38]. However, consent can
be sought at any time before discharge and a discharge notification will still be generated.
Since the DMR referral system and Help for Harry do not generate admission notifications,
consent only needs to be taken before the point of discharge [11,17].
Refer-to-Pharmacy and the DMR referral system allow transfer of information for
patients who cannot consent when the referring professional believes it is in their best
interests to do so. This is acknowledged by a flag in the systems [30,36].
Refer-to-Pharmacy has an inbuilt video to support the consent process. This video
describes the process and the benefits of a referral to help inform patients of the availability
of post-discharge support [28].
Patient Referral Eligibility and Screening
For patients to be referred from one of these transfer of care systems, they must
meet the patient inclusion criteria for the relevant post-discharge support service in their
respective locality. Each of these services has a distinct service delivery model, as described
in Table 3 [11,17,39,40].
Table 3. Service model delivery for post-discharge adherence-support services.
Patient Inclusion Criteria
DMR NMS Discharge MUR
Medication change in hospital New medication for type 2 diabetes, COPD,asthma, hypertension or anticoagulation Taking two or more medications
More than four medications Medication change in hospital
The patient has their medication
dispensed into a compliance aid
Professional judgement
Location of review
• In the pharmacy
• Telephone consultation
• In the patient’s home (with
commissioner’s permission)
• In the pharmacy
• Telephone consultation
• In the pharmacy
• Telephone consultation
• In the patient’s home (with
commissioner’s permission)
Who can receive the review?
Patient or carer Patient only Patient only
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When identifying a patient for post-discharge medicine support through Refer-to-
Pharmacy or the DMR referral system, the referring practitioner is required to select the
patient’s eligibility criteria from a drop-down menu [41]. The system will not allow a
patient to be referred unless one of the criteria is met. PharmOutcomes does not require a
practitioner to specify why patients are eligible, even though the criteria for referral are
shown on the system’s screen [29].
In addition to selecting eligibility criteria, Refer-to-Pharmacy and PharmOutcomes
require the practitioners to stipulate a reason for the referral, for example if they believe the
patient would benefit from a discharge MUR (dMUR), NMS or post-discharge medicines
counselling [28,29]. As the DMR referral system is only used in Wales and has been devel-
oped specifically to refer patients to the DMR service, there is no additional requirement
for a referral reason to be stated.
System Enabled Dissemination of Service Outcomes
Refer-to-Pharmacy sends an automated email to the referring practitioner once a
referral has been actioned. This email contains information about the outcomes of the
service, including what post-discharge service was provided and whether the referral
prevented a discrepancy, and saved time or money. PharmOutcomes provides the referring
practitioner access to data regarding whether the referral was accepted and if so, which
post-discharge service was completed [27,38]. Uniquely, PharmOutcomes will also send a
copy of this report to the patient’s GP surgery if they have an email address registered on
the system [29]. The DMR referral system and Help for Harry provide no routine feedback
to the referring practitioner.
3.2. Method 2 Results: Key Informant Interviews
Three of the four key informants were interviewed between 29 May and 8 July 2019.
The informant for Help for Harry was unable to participate due to a change in their job
role. No further key informants could be identified due to a lack of published information
about the system. Two interviews were completed by phone and one was completed face
to face. These interviews lasted between 45 and 75 min.
Three broad concepts, identified from the literature, were deductively explored in the
data: implementation, stakeholder engagement and system attributes. When the data were
analysed inductively, no further superordinate themes were identified, but sub-themes
were identified which assisted the organisation and analysis of the data. Through this
section, system similarities and differences identified through the interviews are described.
3.2.1. Theme 1. Implementation
The key informants identified ways in which the implementation of the systems
contrasted. These areas include community pharmacist engagement, marketing strategies,
collaboration, dedicated staff and piloting.
Community Pharmacist Engagement
The key informants for two systems discussed how they purposively engaged with
community pharmacists during system implementation, ensuring that they were aware of
the system, knew how to action referrals and were able to receive them.
“There were some people who, again human factors, took a few phone calls to
say “please fill the form in”, “oh yeah we’ll do it now we’ll do it now” and of
course they didn’t so we had to phone them back so again this took a few months
sort of to actually get around to filling out the form to receive the referrals”.
(P2)
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Marketing Strategies
For the implementation of one system, a pre-determined marketing strategy was
used, including regular newsletters to interested parties, speaking on speaker circuits and
creating instructional videos on platforms such as YouTube.
“I wanted to create some sort of marketing strategy, so I got onto speaker’s circuit
at various conferences, started sending out a newsletter to interested parties to
keep them informed of developments and that helped sort of create an awareness
of what we were actually doing”.
(P2)
Collaboration
All key informants discussed the importance of collaborating with local professional
organisations that support the provision of community pharmacy services, such as Com-
munity Pharmacy Wales and Local Pharmaceutical Councils (LPCs). These organisations
helped engage with stakeholders through implementation.
“So then as an LPC, we supported all the contractors, so we spent time showing
them how to use [transfer of care system], how to set up accounts, how to use the
system so by pulling down a report we can see who’s not regularly engaging and
spending time with them making sure they do engage”.
(P3)
Dedicated Staff
Key informants for two systems discussed the importance of employing staff specif-
ically to implement the system. These staff typically organised marketing, developed
materials to support implementation and engaged with stakeholders.
“Yeah yeah well that [funding] paid for me which really helped sort the meetings
at the hospital, ring the pharmacies, develop guides, develop the [transfer of care
system] cos all that takes time really and so we have engagement events so which
is a lot of work we need to get the service up and running”.
(P3)
Piloting
Each system was piloted differently in their locality. One system was piloted with
patients who have their medication dispensed into compliance aids because the transmis-
sion of discharge information for this population was already common by fax. Another
system was piloted geographically, initially implemented in approximately forty-two phar-
macies and then slowly implemented across the rest of the locality. The third system didn’t
undertake a pilot, implementing the system to the entire locality overnight instead.
“No, no, no [we didn’t pilot], it was rolled out across our trust’s footprint in a big
bang way”.
(P2)
3.2.2. Theme 2. System Attributes
The key informants highlighted differences between the attributes of each system,
including IT interoperability, referral prompts and referrals to alternative practitioners.
IT interoperability
IT interoperability was discussed by all of the participants. IT interoperability, between
the transfer of care system and both hospital and community IT systems, was considered a
facilitator to system engagement.
“It [the transfer of care system] populates the form for you, that saves them
[community pharmacists] time as well so all they’ve got to go is “is it the same?”,
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if it’s different, what’s different and tick boxes, so we’ve tried to make it as easy
as possible for them. So, I think it’s probably removed a number of the barriers”.
(P1)
One participant described how the lack of interoperability and integration between
their system and the hospital IT system was a significant barrier for system engagement,
as staff would have to log into the separate application and manually transcribe all the
information.
“It’s still an extra step for them [referring practitioners] I think, it’d be better if
it was integrated into the hospital IT system somehow cos we use a web-based
platform and although it’s a quicker system than using a fax for the trust except
for the departments in the hospital it’s still a lot of logging in and that’s what
they said they’d use it if it was integrated”.
(P3)
Referral Prompts
One participant discussed how their system had inbuilt prompts to encourage the
staff to refer patients for post-discharge support when appropriate. This prompt appears
on the computer screen when a staff member records a patient’s drug history. This was
perceived as being beneficial for system engagement.
“It [transfer of care system] prompts to make a referral if they’re a blister pack
patient or a care home resident so we’re pretty good at making those referrals”.
(P2)
Referrals to Alternative Practitioners
Two participants discussed how their systems have the functionality of referring pa-
tients to different healthcare practitioners. Examples of these include local anticoagulation
clinics, mental health services and domiciliary support teams.
“We also send referrals to what we called a medicines support team so a domicil-
iary pharmacy support service for people from [CCG name] so that’s to arrange
home visits for people who are housebound or can’t easily access community
pharmacy services and they can visit them in their home”.
(P2)
3.2.3. Theme 3. Stakeholder Engagement
The key informants discussed methods by which stakeholder engagement with the
system is encouraged, including accountability for referrals, routine feedback to hospitals
and staff training tools.
Accountability for Referrals
All of the key informants considered that keeping staff accountable for referrals was a
facilitator for system engagement. Staff using two systems kept community pharmacists
accountable for actioning referrals by creating weekly reports for referrals which had not
been actioned, following up those pharmacies by phone to identify any issues.
“I’ve seen some of the other platforms go live and they’ve had no support for
community pharmacists and if you’ve got no-one pulling down a report to see
which pharmacies are doing it, it just gets forgotten about, the pharmacists don’t
know how to use the system and then it just falls, falls apart”.
(P3)
Staff using one system kept the hospital pharmacy staff accountable for referring
patients. They achieved this by giving feedback to pharmacy teams when eligible patients
had been discharged without a referral.
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Feedback of Service Outcomes to Hospitals
The participants discussed the varying levels of feedback that their system provides to
referring practitioners. One system provides automated and anonymised feedback to the
referring practitioner by email, including information on the outcomes of the referral. This
information includes what post-discharge support was provided to the patient, whether
medication discrepancies were prevented and whether the referral saved money or time.
This was considered a facilitator for system engagement as the practitioner would see the
benefit and outcome of their referral.
One participant discussed how their system did not have automated feedback to the
hospital, but the LPC held regular meetings with the hospital pharmacy department to
share information such as the number of referrals made and their outcomes.
“We have regular meetings with the hospital as well so they can see what the
pharmacy is doing, y’know it’s not just going into the ether like a fax was, they
can see all the feedback and they’re loving seeing all the data that pharmacy’s
doing and they’re like “let’s keep going cos, let’s send more referrals, who else
could we refer because pharmacy is really engaging with this so”. So they’re
really enjoying it as well, they’re really happy”.
(P3)
The third system had not yet integrated routine feedback for referring practitioners,
but the participant considered that it would be a facilitator for system engagement and
suggested that it was a planned improvement for the near future.
Staff Training Tools
The key informant for one system described that they have developed a training quiz
to help improve engagement with referrals by increasing staff knowledge.
“So, I thought I’ll do a [transfer of care system] quiz and that’s been used by the
staff to sort of get them into understanding why someone is eligible for referral”.
(P2)
These quizzes are developed from cases where eligible patients were not referred,
giving targeted training to improve knowledge of which patients are eligible for referrals.
4. Discussion
This study used a multi-method approach to describe, compare and contrast UK
technology-supported transfer of care systems. Concepts around development and/or
strategic implementation were explored, and areas were highlighted that could form the
evidence base in the development, implementation or improvement of similar systems.
One difference highlighted by the study arose from the criteria that the different
systems use to screen the eligibility of patients to receive post-discharge support services.
A system should ideally facilitate support to those patients most at risk of post-discharge
medicines mismanagement, increasing the equity of access to healthcare. However, Table 3
illustrates that at present some of the systems cannot refer patients to services if they are
housebound and cannot provide certain services direct to carers, who may be the person
managing the patient’s medicines. It is suggested that more flexible criteria be allowed, to
ensure that those patients most at risk of medication harm where there is a transition of
care can be assured of post-discharge medication support [42–45].
Since the completion of this study, post-discharge support services in England have
changed. As of April 2021, the MUR service is being decommissioned in England [35],
and a new Discharge Medicines Service was commissioned in July 2020 [17]. No new IT
system has been developed for this service and it is suggested that referral to community
pharmacies be done via any secure electronic platform, such as PharmOutcomes, Refer to
Pharmacy or secure NHS email [46]. The eligibility criteria for referral for this new service
can be defined by NHS trusts, but the published toolkit supporting its implementation
described a wide range of broad potential criteria, allowing increased flexibility [47].
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Another important aspect arising from the results is in relation to the interoperability of
the transfer of care systems with wider healthcare IT, a key enabler for the more widespread
adoption of IT. This is one of the priorities for NHS England, as outlined in the NHS
five-year plan; to increase the level of IT utilisation for improvements in care continuity,
including patient discharges from hospital [48]. The Topol review also independently
determined that there is a need to increase IT provision and integration in the NHS [9].
Although there is limited research surrounding the benefits of IT interoperability, systems
that are less interoperable will have an inherently higher risk of transcription errors and
will be more time-consuming, and therefore, are likely to disrupt the workflow of service
users. This challenge was described by participants in the current study, where having
to use a system without extensive IT interoperability was considered as “an extra step”
when referring patients for post-discharge support. The non-adoption, abandonment, scale-
up, spread, sustainability (NASSS) framework asserts that if the technology significantly
disrupts workflow, it is less likely to be adopted [49]; therefore, it is crucial that transfer of
care systems should be interoperable with both hospital and community IT systems.
All systems included in this study had a two-stage process for obtaining patient consent,
in line with clinical governance. However, patient consent is often considered a barrier to
primary care services and has specifically been identified as a barrier to the DMR service
through previous studies, including interviews with community pharmacists [17,50]. A
system feature described by one of the participants was the integration of videos to support
the consent process. Since the evidence for the use of multi-media consent aides in healthcare
is growing, it would be prudent to adopt video consent aides to assist practitioners in gaining
patient consent [51–53].
A key difference between the systems was found to be related to mechanisms for
notifying community pharmacists that one of their patients had been discharged from
hospital, and hence is in need of post-discharge support. It has been reported in the
literature that a lack of awareness for their patients’ discharge is a key barrier for community
pharmacists providing post-discharge support to their patients [17], increasing patient risk
by potentially supplying patients with outdated prescriptions and also increasing potential
medicines waste. Notification systems can be a solution to this problem, with alerts that
should be visible and easily accessible to facilitate community pharmacist awareness of
a patient’s hospital status. Different notification methods can help improve visibility, as
identified in this study, such as the Pharmalarm, and the allowing of email notifications to
be sent to personal NHS email addresses as well as the pharmacy’s work email address.
The use of only a personal email address for these notifications could prove troublesome,
as other pharmacists working in the same premises would not have access.
At the time of data collection, only one of the systems studied enabled the automatic
dissemination of the outcomes of any post-discharge support interaction between the
patient and their community pharmacist back to the hospital practitioner who initiated
the referral. Previous studies with hospital pharmacists who use two UK technology-
supported transfer of care systems reported that such lack of any further feedback feels like
referring patients into a “black hole” [17,18]. Normalisation Process Theory describes how
the implementation and embedding of an innovation is more likely when stakeholders
are able to reflect on its effectiveness [54]. The routine automated feedback described in
the current study would help fulfil this criterion, allowing practitioners to see that their
referral was actioned, and the outcome of the post-discharge service. More systems are
increasing hospital staff access to post-discharge service outcomes: as of April 2020, the
DMR referral system increased its functionality to automatically upload the outcomes of
each DMR service to the shared clinical record in Wales, accessible by hospital pharmacy
staff. During the current COVID-19 pandemic, this feedback is also accessible by GPs [55].
Aspects of the strategic implementation of the different technology-supported transfer
of care systems, described in this study, are supported by a recent systematic review of the
factors affecting the implementation of electronic interventions in healthcare [56], and can
therefore be recommended as good practice. Examples include the use of dedicated staff or
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champions to support the implementation of technology, and suggest that implementation
should be planned, ensuring that service users are adequately trained and stakeholders are
informed of developments in a timely manner. The review also suggests that incremental
piloting is beneficial for the implementation of technology, in contrast to the system that
was implemented to the entire locality overnight [56].
Limitations
Since the end of the data collection period for this study, further developments in
transfer of care systems were introduced in the UK. Even though these developments did
not form part of the results, they have been referenced and included in the discussion
section. The use of grey literature provided extensive information for the description and
comparison of the UK technology-supported transfer of care systems. Although these
sources are not peer reviewed, the areas of good practice were supported by background
literature before being used to draft recommendations.
Despite the fact that the primary researcher is a practising community pharmacist in
Wales, and this could potentially introduce bias in data collection and interpretation, care
was taken to avoid this at every stage of the research process through the use of a reflective
diary and different authors being involved in the quality assurance of data analysis.
Despite the small sample size in the qualitative arm of this study, the authors do
not believe that any bias was introduced. The purpose of the key informant interviews
was to supplement the rapid literature review with the further description of elements of
development or strategic implementation, rather than their perceptions of the systems,
so one participant for each system was considered appropriate. This study focused on
UK technology-supported transfer of care systems, and as such, the transferability of this
study is limited to the UK. However, some of the good practice may be applicable to the
development of international systems.
5. Conclusions
This is the first study to describe, compare and contrast current UK technology-
supported transfer of care systems. Based on the discussions outlined in this paper, the
following timely recommendations are suggested for the development, adaptation and
strategic implementation of technology-supported transfer of care systems:
1. Pre-plan implementation strategies with dedicated staff, focussing on stakeholder
engagement;
2. Flexible notification systems should be developed to inform community pharmacists
of patient admission and discharge, including email and USB device notifications;
3. Produce content such as videos to support patient consent for information transfer;
4. Develop methods to keep hospital and community practitioners accountable for
referrals;
5. Develop interoperability with both hospital and community IT systems to make
referrals seamless;
6. Ensure post-discharge adherence-support services have broad eligibility criteria.
The use of these technologies is likely to be adopted more widely internationally with
the World Health Organisation’s focus on improving medication safety during transitions
of care, and in the UK with the recent announcement in England of the Discharge Medicines
Service [18,57]. Further work to explore stakeholder perceptions of these systems would
provide more evidence of service users’ perspectives.
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Appendix A
(1) Could you explain a bit about the history of DMR/Refer-To-Pharmacy/Pharmoutcomes/
Help for Harry?
a. Why was it set up?
(2) Could you please take me through a step by step process of the service from identifi-
cation of patients to post-discharge follow-up
(3) How is patient consent managed throughout the service?
a. Hospital consent (what is this for?)
b. Community consent (what is this for?)
(4) What data are routinely collected through each service?
a. Medication names
b. Number of discrepancies
c. Outcome of referral
d. Demographics
(5) How many pharmacies currently provide this service? (clarify if this is increasing)
a. How many did it start with, as a pilot?
b. Is this still increasing?
c. How have you managed to get pharmacies on board?
(6) Through research on DMRs, it was found that many hospital staff felt that they initiate the
scheme but see no end-product. What feedback is routinely provided to hospital staff?
a. How is this recorded?
(7) How do community pharmacists receive notification that a patient has been dis-
charged from hospital? (clarify whether personal/NHS email, etc.)
a. Has this changed since inception of the service?
b. Do you see any issues with these methods?
c. Any additional notifications provided? (admission)
(8) What do you consider are the barriers to the provision of RTF/DMR/PharmOutcomes?
a. Have these changed over time?
(9) What do you consider are the facilitators to the provision of RTP/DMR/Pharmoutcomes/
Help for Harry?
a. Have these changed over time?
(10) What, if any, improvements or advances are planned in the foreseeable future for this
service?
a. Are changes in services based on service evaluations?
b. What further service evaluations are planned and how do you hope these will
implement further change?
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Do you have any further comments or information you think would be useful?
[Prompt—summarise all key points to ensure accurate data collection].
Thank you again for your time.
Appendix B
Table A1. Summary for Reporting Qualitative Research items and their corresponding lines within the text.
Summary for Reporting Qualitative Research Item CorrespondingLine(s)
Item 1. Title: Concise description of the nature and topic of the study. Identifying the study as qualitative or indicating the
approach (e.g., ethnography, grounded theory) or data collection methods (e.g., interview, focus group) is recommended. 2–3
Item 2. Abstract: Summary of key elements of the study using the abstract format of the intended publication; typically includes
background, purpose, methods, results, and conclusions. 13–28
Item 3. Problem Formulation: Description and significance of the problem/phenomenon studied; review of relevant theory and
empirical work; problem statement. 32–73
Item 4. Purpose or research question: Purpose of the study and specific objectives or questions. 70–76
Item 5. Qualitative approach and research paradigm: Qualitative approach (e.g., ethnography, grounded theory, case study,
phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g., post-positivist,
constructivist/interpretivist) is also recommended; rationale.
115–118
Item 6. Researcher characteristics and reflexivity: Researchers’ characteristics that may influence the research, including personal
attributes, qualifications/experience, relationship with participants, assumptions, and/or presuppositions; potential or actual
interaction between researchers’ characteristics and the research questions, approach, methods, results and/or transferability.
143–149
Item 7. Context: Setting/site and salient contextual factors; rationale. 126–134
Item 8. Sampling strategy: How and why research participants, documents, or events were selected; criteria for deciding when no
further sampling was necessary (e.g., sampling saturation); rationale. 126–134
Item 9. Ethical issues pertaining to human subjects: Documentation of approval by an appropriate ethics review board and
participant consent, or explanation for lack thereof; other confidentiality and data security issues. 122–125
Item 10. Data collection methods: Types of data collected; details of data collection procedures including (as appropriate) start and
stop dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in
response to evolving study findings; rationale.
135–142
Item 11. Data collection instruments and technologies: Description of instruments (e.g., interview guides, questionnaires) and
devices (e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study.
Appendix A
122–124
Item 12. Units of study: Number and relevant characteristics of participants, documents, or events included in the study; level of
participation. 126–134
Item 13. Data processing: Methods for processing data prior to and during analysis, including transcription, data entry, data
management and security, verification of data integrity, data coding and anonymization/de-identification of excerpts. 135–142
Item 14. Data analysis: Process by which inferences, themes, etc., were identified and developed, including the researchers
involved in data analysis; usually references a specific paradigm or approach; rationale. 135–142
Item 15. Techniques to enhance trustworthiness: Techniques to enhance trustworthiness and credibility of data analysis, (e.g.,
member checking, triangulation, audit trail); rationale. 141–142
Item 16. Synthesis and interpretation: Main findings (e.g., interpretations, inferences, and themes); might include development of a
theory or model, or integration with prior research or theory. 265–409
Item 17. Links to empirical data: Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings. 265–409
Item 18. Integration with prior work, implications, transferability, and contribution(s) to the field: Short summary of main findings,
explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship;
discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field.
410–485
Item 19. Limitations: Trustworthiness and limitations of findings. 486–503
Item 20. Conflicts of interest: Potential sources of influence or perceived influence on study conduct and conclusions; how these
were managed. 530
Item 21. Funding: Sources of funding and other support; role of funders in data collection, interpretation, and reporting. 527–528
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